touchCONGRESS

PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice

Access to this content is not permitted for healthcare professionals based in the US.

Back to Education
Gynaecological Cancers, Ovarian Cancer Watch Time: 61 mins

touchCONGRESS PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice

Watch this two-part activity exploring recent developments on the use of PARP inhibitors as first-line maintenance therapy in ovarian cancer. Filmed following the SGO Virtual Annual Meeting 2021.

Part 1: Watch gynaecological cancer expert Dr Alexandra Leary review key data from the SGO Virtual Annual Meeting 2021 Watch Now
Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview

  • Part 1: Data Review
Next Chapter
Introduction
Update on PARP inhibitors as first-line maintenance therapy
Emerging real-world outcomes with PARP inhibitors
Factors guiding treatment decisions surrounding PARP inhibitors in first-line maintenance therapy
Video Player Controls:
 
Leave Feedback
  • Part 2: Expert Interviews
Leave Feedback
Prof. Nicoletta Colombo
Watch Time: 12:20 University of Milan-Bicocca, Milan, Italy

Nicoletta Colombo considers the latest data on PARP inhibitors as first-line maintenance therapy in advanced ovarian cancer, presented at SGO Virtual 2021.
 
 
Leave Feedback
Prof. Keiichi Fujiwara
Watch Time: 08:47 Saitama Medical University International Medical Center, Saitama, Japan

Keiichi Fujiwara considers the latest data on PARP inhibitors as first-line maintenance therapy in advanced ovarian cancer, presented at SGO Virtual 2021.

 
 
 
Leave Feedback
Dr Alexandra Leary
Watch Time: 09:33 Gustave Roussy, Villejuif, France

Alexandra Leary considers the latest data on PARP inhibitors as first-line maintenance therapy in advanced ovarian cancer, presented at SGO Virtual 2021.
 
 
Leave Feedback
Please Select A Video:
Prof. Nicoletta Colombo
 University of Milan-Bicocca, Milan, Italy Watch Time: 12:20 Translations available:
Watch Video
Prof. Keiichi Fujiwara
 Saitama Medical University International Medical Center, Saitama, Japan Watch Time: 08:47 Translations available:
Watch Video
Dr Alexandra Leary
 Gustave Roussy, Villejuif, France Watch Time: 09:33 Translations available:
Watch Video
Leave Feedback
Overview & Learning Objectives
Overview

Get an update on the use of PARP inhibitors as first-line maintenance treatment for ovarian cancer in this two-part activity. Filmed following the SGO Virtual Annual Meeting 2021.

Learning Objectives

After watching this activity, participants should be better able to:

  • Recall the latest data for PARP inhibitors for first-line maintenance treatment and how they may impact clinical practice
  • Describe the latest safety data for the PARP inhibitors
  • Define the different factors that influence treatment selection of PARP inhibitor therapy in the first-line maintenance setting
Register to touchONCOLOGY for FREE
  • Peer-reviewed journals and expert opinions
  • Interactive CME and e-learning modules
  • Video conference highlights
Register For Free Now
This Activity Is Funded By:

An independent medical education grant from GlaxoSmithKline. This activity is provided by touchIME.

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

This content is intended only for healthcare professionals.

Launch date: 22 April 2021.

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchCONGRESS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

* = Mandatory Field

Feedback Close
Feedback

Thank you for your feedback.

Back to Activity
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72